Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical trial data and emerging strategies: HER2-positive breast cancer
Sònia Pernas, Sara M. Tolaney
Breast Cancer Research and Treatment (2022) Vol. 193, Iss. 2, pp. 281-291
Closed Access | Times Cited: 20

Showing 20 citing articles:

Current status and future expectations of nanobodies in oncology trials
Tessa De Pauw, Lynn De Mey, Jens Debacker, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 8, pp. 705-721
Open Access | Times Cited: 18
Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer
Mónica Cejuela Solís, Andrea Vethencourt, Sònia Pernas
Current Oncology Reports (2022) Vol. 24, Iss. 12, pp. 1801-1819
Closed Access | Times Cited: 24
Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
Manuel Gámez-Chiachio, David Sarrió, Gema Moreno‐Bueno
Cancers (2022) Vol. 14, Iss. 18, pp. 4543-4543
Open Access | Times Cited: 19
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial
Zheqi Li, Otto Metzger, Giuseppe Viale, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 7
Open Access | Times Cited: 4
Prediction of HER2 status via random forest in 3257 Chinese patients with gastric cancer
Shan Tian, Rong Yu, Fangfang Zhou, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 8, pp. 5015-5024
Closed Access | Times Cited: 5
Nanoparticle delivery of TFOs is a novel targeted therapy for HER2 amplified breast cancer
Xiaojing Yang, Yi Xu, Jie Fu, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 5
GPR81-mediated reprogramming of glucose metabolism contributes to the immune landscape in breast cancer
Xiaofeng Li, Yiwen Chen, Ting Wang, et al.
Discover Oncology (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Efficacy and safety of Trastuzumab Emtansine in treating human epidermal growth factor receptor 2-positive metastatic breast cancer in Chinese population: a real-world multicenter study
Miao He, Wen Zhao, Peng Wang, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 1
Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer
Chunyu Tian, Minghui Wang, Hancheng Liu, et al.
Irish Journal of Medical Science (1971 -) (2022) Vol. 192, Iss. 3, pp. 1041-1049
Closed Access | Times Cited: 6
RAB10 promotes breast cancer proliferation migration and invasion predicting a poor prognosis for breast cancer
Jian Zhuo, Jianjun Han, Yanchun Zhao, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 3
Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer
明强 石
Advances in Clinical Medicine (2024) Vol. 14, Iss. 02, pp. 4428-4434
Closed Access
DNA Methylation-Regulated HOXC8’s Role in HER2-Positive Breast Cancer Function and its Contribution to Herceptin Resistance
Xiaofeng Xie, Sijia Tang, Zhengyang Yu
Discovery Medicine (2024) Vol. 36, Iss. 182, pp. 559-559
Open Access
Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review
Yanfang Lan, Jiahui Zhao, Fangrui Zhao, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Trastuzumab-functionalized SK-BR-3 cell membrane-wrapped mesoporous silica nanoparticles loaded with pyrotinib for the targeted therapy of HER-2-positive breast cancer
Xing Liu, Wenwen Shen
International Journal of Pharmaceutics X (2024) Vol. 8, pp. 100302-100302
Open Access
Immunomorphological specifcity of HER2-low breast cancer
И. В. Михайлов, Elizaveta R. Eremeeva, А. А. Глазков, et al.
Siberian Journal of Oncology (2024) Vol. 23, Iss. 5, pp. 47-58
Open Access
HER-2 expression in colorectal cancer and its correlation with immune cell infiltration
Di Yang, Bo Wang, Yinuo Li, et al.
(2023)
Open Access | Times Cited: 1
HER-2 Expression in Colorectal Cancer and Its Correlation with Immune Cell Infiltration
Di Yang, Bo Wang, Yinuo Li, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 2889-2889
Open Access | Times Cited: 1
Can neoadjuvant systemic therapy provide additional benefits for T1 HER2+ breast cancer patients: a subgroup analysis based on different high-risk signatures
Lidan Chang, Dandan Liu, Xuyan Zhao, et al.
Clinical & Translational Oncology (2024) Vol. 26, Iss. 9, pp. 2323-2338
Closed Access
Integrated multiomics analyses unveil the implication of a costimulatory molecule score on tumor aggressiveness and immune evasion in breast cancer: A large-scale study through over 8,000 patients
Dong Zhang, Yingnan Wang, Faming Zhao, et al.
Computers in Biology and Medicine (2023) Vol. 159, pp. 106866-106866
Open Access
Evaluation of homodimer 99mTc-HYNIC-E(SSSLTVPWY)2 peptide on HER2-over expressed breast cancer cells
Fatemeh Ebrahimi, Zohreh Noaparast, Seyed Jalal Hosseinimehr
Medicinal Chemistry Research (2023) Vol. 32, Iss. 6, pp. 1178-1189
Closed Access
Page 1

Scroll to top